JP2017538673A5 - - Google Patents

Download PDF

Info

Publication number
JP2017538673A5
JP2017538673A5 JP2017522809A JP2017522809A JP2017538673A5 JP 2017538673 A5 JP2017538673 A5 JP 2017538673A5 JP 2017522809 A JP2017522809 A JP 2017522809A JP 2017522809 A JP2017522809 A JP 2017522809A JP 2017538673 A5 JP2017538673 A5 JP 2017538673A5
Authority
JP
Japan
Prior art keywords
optionally substituted
substituted
pharmaceutical composition
alkyl
leukemia
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2017522809A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017538673A (ja
JP6588546B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2015/002438 external-priority patent/WO2016067112A1/en
Publication of JP2017538673A publication Critical patent/JP2017538673A/ja
Publication of JP2017538673A5 publication Critical patent/JP2017538673A5/ja
Application granted granted Critical
Publication of JP6588546B2 publication Critical patent/JP6588546B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2017522809A 2014-10-31 2015-10-26 新規抗癌剤としての置換2,4ジアミノキノリン Active JP6588546B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462073325P 2014-10-31 2014-10-31
US62/073,325 2014-10-31
PCT/IB2015/002438 WO2016067112A1 (en) 2014-10-31 2015-10-26 Substituted 2,4 diamino-quinoline as new anticancer agents

Publications (3)

Publication Number Publication Date
JP2017538673A JP2017538673A (ja) 2017-12-28
JP2017538673A5 true JP2017538673A5 (cg-RX-API-DMAC7.html) 2018-11-15
JP6588546B2 JP6588546B2 (ja) 2019-10-09

Family

ID=55404745

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017522809A Active JP6588546B2 (ja) 2014-10-31 2015-10-26 新規抗癌剤としての置換2,4ジアミノキノリン

Country Status (34)

Country Link
US (1) US10722505B2 (cg-RX-API-DMAC7.html)
EP (1) EP3212629B1 (cg-RX-API-DMAC7.html)
JP (1) JP6588546B2 (cg-RX-API-DMAC7.html)
KR (1) KR102548547B1 (cg-RX-API-DMAC7.html)
CN (1) CN107148416B (cg-RX-API-DMAC7.html)
AU (1) AU2015338844B2 (cg-RX-API-DMAC7.html)
CA (1) CA2965262C (cg-RX-API-DMAC7.html)
CL (1) CL2017001073A1 (cg-RX-API-DMAC7.html)
CO (1) CO2017007325A2 (cg-RX-API-DMAC7.html)
CR (1) CR20170177A (cg-RX-API-DMAC7.html)
CY (1) CY1121326T1 (cg-RX-API-DMAC7.html)
DK (1) DK3212629T3 (cg-RX-API-DMAC7.html)
DO (1) DOP2017000107A (cg-RX-API-DMAC7.html)
EA (1) EA037119B1 (cg-RX-API-DMAC7.html)
EC (1) ECSP17026748A (cg-RX-API-DMAC7.html)
ES (1) ES2707125T3 (cg-RX-API-DMAC7.html)
GE (1) GEP20207108B (cg-RX-API-DMAC7.html)
HR (1) HRP20190107T1 (cg-RX-API-DMAC7.html)
IL (1) IL251775B (cg-RX-API-DMAC7.html)
LT (1) LT3212629T (cg-RX-API-DMAC7.html)
MA (1) MA40875B1 (cg-RX-API-DMAC7.html)
MY (1) MY193740A (cg-RX-API-DMAC7.html)
NI (1) NI201700052A (cg-RX-API-DMAC7.html)
PE (1) PE20191142A1 (cg-RX-API-DMAC7.html)
PH (1) PH12017500810A1 (cg-RX-API-DMAC7.html)
PL (1) PL3212629T3 (cg-RX-API-DMAC7.html)
PT (1) PT3212629T (cg-RX-API-DMAC7.html)
RS (1) RS58328B1 (cg-RX-API-DMAC7.html)
SG (1) SG11201703479SA (cg-RX-API-DMAC7.html)
SI (1) SI3212629T1 (cg-RX-API-DMAC7.html)
TN (1) TN2017000168A1 (cg-RX-API-DMAC7.html)
TR (1) TR201900148T4 (cg-RX-API-DMAC7.html)
UA (1) UA122062C2 (cg-RX-API-DMAC7.html)
WO (1) WO2016067112A1 (cg-RX-API-DMAC7.html)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI3452465T1 (sl) * 2016-05-04 2021-04-30 Genoscience Pharma Substituirani derivati 2,4-diamino-kinolina za uporabo v zdravljenju proliferativnih bolezni
US11065265B2 (en) 2018-05-18 2021-07-20 Spes Pharmaceuticals Inc. Compositions of fosaprepitant and methods of preparation
EP3620164A1 (en) * 2018-09-05 2020-03-11 Genoscience Pharma SAS Substituted 2,4 diamino-quinoline as new medicament for fibrosis, autophagy and cathepsins b (ctsb), l (ctsl) and d (ctsd) related diseases
WO2020092528A1 (en) 2018-10-31 2020-05-07 Gilead Sciences, Inc. Substituted 6-azabenzimidazole compounds having hpk1 inhibitory activity
ES2979163T3 (es) 2018-10-31 2024-09-24 Gilead Sciences Inc Compuestos de 6-azabenzimidazol sustituidos como inhibidores de HPK1
EP3972695A1 (en) 2019-05-23 2022-03-30 Gilead Sciences, Inc. Substituted exo-methylene-oxindoles which are hpk1/map4k1 inhibitors
WO2022033459A1 (zh) * 2020-08-10 2022-02-17 萧乃文 双非癌药物用于制备治疗癌症的医药组合物的用途
CN112375081B (zh) * 2020-11-23 2022-04-12 中国医学科学院医药生物技术研究所 具有抑制CDK4、6或9活性的吡咯[2,3-d]嘧啶衍生物及其制备方法和应用
CN112876673B (zh) * 2021-01-25 2021-12-24 山东大学 一种pH响应性纳米共聚物载体及其制备方法和应用
EP4349336A1 (en) 2022-10-04 2024-04-10 Genoscience Pharma Combination of substituted 2,4 diamino-quinoline compounds and mek inhibitors for use in the treatment of liver cancers
EP4520396A1 (en) 2023-09-05 2025-03-12 Genoscience Pharma Crystalline freebase form of 2-(4-chlorobenzylamino)-4-(4-tert-butylaminopiperidin-1-yl)-quinoline and uses thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PA8580301A1 (es) * 2002-08-28 2005-05-24 Pfizer Prod Inc Nuevos derivados de benzoimidazol utiles como agentes antiproliferativos
EP1571146A4 (en) * 2002-12-10 2010-09-01 Ono Pharmaceutical Co NITROGENIC HETEROCYCLIC COMPOUNDS AND THEIR MEDICAL USE
EP1601357A4 (en) * 2003-03-10 2007-10-03 Schering Corp HETEROCYCLIC KINASE INHIBITORS: METHOD OF USE AND SYNTHESIS
AR094664A1 (es) * 2013-01-15 2015-08-19 Incyte Corp Compuestos de tiazolcarboxamidas y piridinacarboxamida utiles como inhibidores de quinasa pim
US10179770B2 (en) * 2013-03-18 2019-01-15 Genoscience Pharma Quinolines derivatives as novel anticancer agents

Similar Documents

Publication Publication Date Title
JP2017538673A5 (cg-RX-API-DMAC7.html)
JP2016519091A5 (cg-RX-API-DMAC7.html)
AU2021225157B2 (en) Combination therapy of tetracyclic quinolone analogs for treating cancer
JP2019503674A5 (cg-RX-API-DMAC7.html)
WO2008076278A4 (en) Methods of cancer treatment with igf1r inhibitors
KR102548547B1 (ko) 신규한 항암제로서의 치환 2,4 디아미노-퀴놀린
RU2017145267A (ru) Модуляторы протеолиза на основе имидов и связанные с ними способы применения
US10086010B2 (en) Synergistic enhancement of 5-fluorouracil cytotoxicity by deoxyuridine analogs in cancer cells
JP2011515478A5 (cg-RX-API-DMAC7.html)
JP2023538517A (ja) Retの標的分解のための化合物
JP2012247438A5 (cg-RX-API-DMAC7.html)
KR102846292B1 (ko) Etbr 활성화와 관련된 암을 치료하기 위한 중수소화 화합물, 조성물, 및 방법
US10512651B2 (en) Inhibition of MK2 in the treatment of cancer
AU2018291026A1 (en) Morphic forms of GIT38 and methods of manufacture thereof
WO2021257587A1 (en) Morphic forms of trilaciclib and methods of manufacture thereof
US20160368980A1 (en) Inhibition of granulocyte colony stimulating factor in the treatment of cancer
CA3147639A1 (en) Treatment of urothelial and kidney cancers by use of endothelin b receptor antagonists
JPWO2021055705A5 (cg-RX-API-DMAC7.html)
US20160184356A1 (en) Arsenic-based treatment of cancers and inflammatory disorders
RU2786570C2 (ru) Комбинированная терапия тетрациклическими аналогами хинолона для лечения рака
CA3218436A1 (en) Ripretinib for treating melanoma
EA046650B1 (ru) Дейтерированные соединения, композиции и способы для лечения рака, связанного с активацией etbr
HK1261603A1 (en) Combination therapy of tetracyclic quinolone analogs for treating cancer
HK1261603B (en) Combination therapy of tetracyclic quinolone analogs for treating cancer